-
The Lancet: Study confirms cardiovascular benefits of semaglutide beyond weight loss
23 Oct 2025 00:38 GMT
COI Statement
JD declares having received consulting honoraria from Aegerion,
Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis,
Novo Nordisk, Pfizer, Sanofi, and Takeda; and research grants from
Aegerion, Alzheimer’s Research UK, British …
-
Chronic Obstructive Pulmonary Disease Drugs Market to Reach USD 30.13 Billion by 2032
24 Oct 2025 06:48 GMT
… . Europe, the second-largest market, benefits from sophisticated healthcare systems, proactive … Ltd. (India)
Cipla Limited (India)
Daiichi Sankyo Company, Limited (Japan)
Zydus Cadila …
-
<![CDATA[Tolerability and PFS Benefit Shown for Sirexatamab in DKK1-High mCRC]]>
19 Oct 2025 19:43 GMT
… DKK1-high subgroup demonstrated a benefit in progression-free survival (PFS … , Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo Company, Eli Lilly and Company …
-
Sacituzumab govitecan improves outcomes for breast cancer subset
23 Oct 2025 20:23 GMT
… vs. 24%).
Researchers observed PFS benefit across subgroups, including based on … received sacituzumab govitecan derived significant benefit (median PFS2, 18.2 … , with AbbVie, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly & Co., Gilead …
-
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
22 Oct 2025 15:19 GMT
… game is AstraZeneca with its Daiichi Sankyo–partnered ADC Datroway. At ESMO … , in our view,” for the benefit of ivonescimab as a frontline …
-
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
22 Oct 2025 07:57 GMT
… Gilteritinib achieved significant overall survival benefit over chemotherapy in relapsed… reports personal fees from AstraZeneca, Daiichi Sankyo, Pfizer, Lilly, Genentech, Regeneron, Johnson …
-
‘We need to pick a lane’: Lilly oncology president weighs in on FDA cancer drug policies
22 Oct 2025 04:02 GMT
… this past weekend, AstraZeneca and Daiichi Sankyo’s Datroway showed in the … able to show a survival benefit against chemo in the same …
-
T-Dxd may be new standard for high-risk breast cancer
21 Oct 2025 22:45 GMT
… Fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi-Sankyo, AstraZeneca) improved invasive DFS by … and safety.
‘Clinically meaningful’ benefit
Median study duration reached 29 … said.
The invasive DFS benefit persisted across subgroups.
Trastuzumab deruxtecan …
-
Merck grows more ambitious about 'workhorse' TROP2 ADC as partner Kelun posts phase 3 wins
21 Oct 2025 00:23 GMT
… in the chemo group.
Benefits were observed across subgroups … .
Sac-TMT’s PFS benefit was also statistically significant, … 11.
Besides the OS benefit, sac-TMT also comes … racing against AstraZeneca, whose Daiichi Sankyo-partnered Datroway is being paired …
-
Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight
20 Oct 2025 23:43 GMT
… reducing local recurrence, while the benefits of perioperative radiotherapy remain uncertain … , OncoResponse, Inc., Adaptimmune, Incyte Corporation, Daiichi Sankyo, Numab Therapeutics AG, HRYZ Biotech …
About
© 1995-2025